Fresenius is integrated into a diverse network of interest groups. From this exchange, we gain valuable insights that help us to continuously improve the management of material topics and reporting.
Our Approach
We engage with our stakeholders through a variety of channels. The corporate functions at Fresenius primarily focus on stakeholders who are relevant to the Group as a whole. The Operating Companies actively engage with patients, employees, customers, and regulatory authorities, among others.
For the integration of potentially affected stakeholders in our operating activities, we consider, for example, findings from existing due diligence processes and risk assessments in quality, internal employee satisfaction surveys, dialogs with employee representatives and works councils, patient and customer surveys.
➔ Read more in our Sustainability Statement.
Initiatives & Memberships
An important element of our stakeholder dialogs is our active participation in industry and interest groups, as well as our exchange with business partners. Our employees contribute their expertise to national and international bodies, committees, and associations.
We are committed to observing the codes and principles associated with our membership in various associations. In addition, we disclose all contributions made to healthcare professionals in the companies of Fresenius in accordance with the applicable disclosure requirements.
Fresenius has a Sponsored Level 1 American Depositary Receipt (ADR) Program in the United States. The ADRs are traded under the ticker symbol "FSNUY" in the over-the-counter market tier.
ADR information
Structure | Sponsored Level 1 ADR |
Ratio (ADR:ORD) | 4:1 |
Trading Location | OTC |
Ticker Symbol | FSNUY |
CUSIP | 35804M105 |
ISIN | US35804M1053 |
Trading in ADR
ADRs represent ordinary or common shares of a non-U.S. company. Four Fresenius ADRs are the equivalent of one Fresenius ordinary share. They are priced in U.S. dollars and traded in the U.S. over-the-counter (OTC) market. J.P. Morgan Chase Bank N.A is acting as the depositary bank for this ADR program.
Contact details for ADR brokers & institutional investors:
U.S. Tel: +1 212 552 8926
Hong Kong Tel: +852 2800 1857
e-mail: drx_depo@jpmorgan.com
Computershare contacts for ADR registered holders of Fresenius:
Computershare Shareowner Services
Phone (US & Canada – toll free): +1-866-723-8257
Phone (International): +1-781-575-2833
For regular correspondence:
Computershare Shareowner Services
P.O. Box 43304 Providence, RI 0290-3304, USA
Email: web.queries@computershare.com
Website: www.computershare.com/investor or www.computershare.com/us/contact-us
For delivery of stock certificates & overnight mail:
Computershare Trust Company, N.A
150 Royall Street
Canton, MA 02021
Fresenius’ ADR program is administered by J.P. Morgan Chase Bank N.A. As the depositary bank, J.P. Morgan Chase Bank N.A performs the following roles for registered ADR holders as further detailed in the Deposit Agreement:
- Records and maintains the register of ADR holders,
- Is the stock transfer agent,
- Distributes dividends in U.S. dollars,
- Facilitates the voting process and the exercise of the voting rights of ADR holders at any Company General Meeting if permitted by the Company and the Depositary Agreement,
- Issues and cancels Fresenius American Depositary Receipts (ADRs),
- Can distribute Company circulars and General Meetings (including Annual General Meeting) documentation, if applicable.
For those holders who are not registered because their ADRs are held through a ‘Street name’ (nominee account), your nominee will from time to time receive Company documents from J.P. Morgan Chase Bank N.A to distribute to ADR holders. You need to make arrangements with your nominee if you wish to receive such documents and to be able to exercise your vote through the depositary bank at General Meetings (if applicable).
Contact
Director Investor Relations
T: +49 (0) 6172 608-5211
stefanie.drees@fresenius.com
Related Links
Historical ADR prices and interactive chartsAs a global healthcare company, our actions are guided by clear principles, standards, and governance structures. They form the basis for acting responsibly and with integrity across the Group.
Within our Sustainability Framework, the Ethical Foundation defines how we embed ethical behavior in our processes, decisions, and relationships. This includes ensuring compliance, respecting human rights, and maintaining clear standards for responsible and ethical conduct. It also includes our commitment to quality, which is essential to ensuring the safety and reliability of our products and services.
Integrity is the foundation of trust – within our organization and in our interactions with patients, partners, regulators, and society. We aim to foster a culture where ethical behavior and quality are consistently reflected in how we operate.
The Ethical Foundation of our Sustainability Framework encompasses the following focus topics:
For us, quality excellence means a commitment to providing leading product and service quality and safety, driven by continuous improvement and effectiveness. We want to bring healthcare innovations to the people and thus provide value for patients.
Since our operations encompass healthcare services, pharmaceuticals, and medical technology, the quality requirements naturally vary. Our quality management systems are specifically designed to address these diverse needs, meeting both internal standards and external requirements. We ensure this through robust processes and comprehensive training programs across all areas of our business. To track our performance, we use clearly defined quality indicators and targets. These are not only embedded in our daily work but also tied to the variable compensation of our Management Board.
➔ Read more in our Sustainability Statement.
Innovation is key to meeting the needs of our patients – today and in the future. For us, it is a driving force behind improving treatment options, streamlining workflows, and delivering high-quality healthcare solutions. Our integrated approach spans the entire value chain and focuses, among other things, on initiatives that enhance therapies and patient experience through research, telemedicine, and Artificial Intelligence.
The quality of our products, services, and therapies is the basis for optimal medical care.
➔ Read more in our Sustainability Statement.
We are committed to respecting human rights.
Patients, doctors, nursing and administrative staff rely on our products, concepts, and solutions. Around 180,000 employees place their trust in Fresenius as an employer. At the same time, we rely on thousands of people worldwide who work for our suppliers and business partners in our value chain.
Our Human Rights Program is based on internationally recognized standards and frameworks, including the Universal Declaration of Human Rights, the Core Labor Standards of the International Labour Organization, the UN Guiding Principles on Business and Human Rights, and the OECD Due Diligence Guidance for Responsible Business Conduct.
Our commitment to respect human rights is an integral part of our responsibility as a global healthcare company.
➔ Read more on our Human Rights page.
We are committed to high ethical business standards – out of responsibility toward patients, employees, the environment, and society.
We believe in doing the right thing. That means acting not only in line with legal requirements, but also in accordance with industry codes, internal policies, and our values – the Fresenius Principles. Internal and external controls help ensure compliance and safeguard the trust our stakeholders place in us.
No matter the role, our work is grounded in the Fresenius Code of Conduct.
➔ Read more on our Compliance page.
Sustainability Insights
Explore our stories to learn what sustainability looks like in our daily operations:
-
HeSaMeDa: Using data securely for better care
With diagnostic and therapeutic information, test samples from the laboratory, and other treatment data – hospitals are sitting on a wealth of data. Evaluating this data can help to better understand the relationships between therapy procedures and treatment outcomes, identify patterns, and develop innovative treatment methods.
-
Enhancing patient experience: Bridging digital care and energy consumption
Enhancing patient experience is one of Fresenius’ top priorities – and digitalization plays an important role in achieving this. In 2025, Quirónsalud launched a pilot project at a hospital in Southern Spain to connect our digital platform Casiopea with the hospital’s Building Management System.
-
What exactly is … a hospital cluster?
Fresenius Helios has grouped its roughly 80 hospitals in Germany into 21 clusters. The aim is to deliver patient care while further enhancing medical quality and efficiency.
-
Resistant pathogens: Prevention in hospitals and when manufacturing antibiotics
Antibiotics play a key role in modern medicine. They treat bacterial infections and prevent them from spreading. In certain cases, however, their reliability can no longer be relied upon. That’s because antimicrobial resistance – the incidence of resistant pathogens – is spreading worldwide.
As a healthcare company, we operate in a demanding environment where patient safety and hygiene requirements are always a top priority. At the same time, we are committed to reducing the environmental impact of our activities.
Within our Sustainability Framework, the Planet Dimension, we focus on minimizing our environmental footprint, contributing to climate protection, and using natural resources responsibly, including water and materials, and reducing waste. In doing so, we aim to balance environmental responsibility with the requirements of high-quality patient care.
We recognize that a healthy environment is closely linked to human health. By reducing the environmental impact of our operations, we aim to contribute to climate protection and the responsible use of natural resources – today and in the future.
The Planet Dimension of our Sustainability Framework encompasses the following focus topics:
We have a clear target: net zero emissions from our own operations and along our value chain by 2050.
Fresenius manufactures medical products and operates healthcare facilities, which inevitably results in energy consumption and associated greenhouse gas emissions. In production, for example, the machines and containers have to be sterilized, and in our hospitals a wide variety of technical systems are in constant operation. This presents us with special challenges: On the one hand, we want to reduce our energy demand as far as possible and on the other hand, we must always guarantee the safety of patients in our facilities and ensure a stable supply of energy in our production.
We want to live up to our responsibilities and help achieve the goal of the Paris Climate Agreement: Our climate targets aim to limit global warming to 1.5 °C. All our climate protection activities contribute to our long-term objective of attaining net zero by 2050: This requires a company to reduce its avoidable greenhouse gas emissions, while unavoidable emissions must be offset by removing an equivalent amount from the atmosphere and storing it for the long term.
Within our own operations, we are committed to reducing our Scope 1 and Scope 2 emissions by 50% by 2030.
Scope 1 and Scope 2 target pathway to 2030
The decarbonization of our value chain is a decisive factor on our long-term path to net zero. Scope 3 emissions include greenhouse gases that are released indirectly in our upstream and downstream value chains – such as from purchased raw materials or at the end of the life of sold products.
Climate change is also a health issue. Rising temperatures, more frequent heatwaves and changing weather patterns directly affect people's health, particularly vulnerable groups such as the elderly, chronically ill, and children. Heat stress can lead to circulatory problems, dehydration and an increased risk of death. At the same time, climate change contributes to the spread of infectious diseases, for example by introducing new vectors such as mosquitoes or contaminating water sources. As a healthcare company, we therefore consider it our responsibility to not only react to the effects of climate change, but also actively contribute to mitigating it. After all, climate protection is health protection.
We place particular emphasis on preserving water quality. In water-stressed areas, we are especially committed to reducing our water withdrawal.
Water is one of our most valuable resources. As a healthcare company, we are dependent on water: We need drinking water of the highest quality to ensure safe patient care. It is crucial for hygiene and well-being. We also use water in the production of our pharmaceutical products – as process water as well as product component. The quality requirements for this water are even higher than those for drinking water.
It is our ambition to avoid or minimize any negative impact on the environment that may arise from our direct business operations or from downstream activities. This also includes avoiding unnecessarily polluting the sources from which we obtain water or into which we discharge our wastewater.
At Fresenius, we focus on reducing our waste and embedding circular principles into product design and packaging solutions.
We are committed to conserving natural resources wherever possible. In doing so, we always have to strike a balance between resource efficiency and hygiene requirements. Disposable items are often used in clinics for hygienic reasons. Our options for saving resources are limited here. There are also strict regulations for pharmaceutical packaging. Our most important levers for conserving resources are therefore developing durable and resource-saving products, reusing resources wherever possible, and disposing of waste safely and systematically.
Sustainability Insights
Explore our stories to learn what sustainability looks like in our daily operations:
-
Resistant pathogens: Prevention in hospitals and when manufacturing antibiotics
Antibiotics play a key role in modern medicine. They treat bacterial infections and prevent them from spreading. In certain cases, however, their reliability can no longer be relied upon. That’s because antimicrobial resistance – the incidence of resistant pathogens – is spreading worldwide.
-
What do anesthetic gases have to do with the climate?
Anesthetic gases are an indispensable part of modern medicine. At the same time, they represent one of the largest direct sources of emissions in hospital operations, with their global warming potential exceeding that of CO2 many times over. Thanks to modern medical technology, special systems can be used to capture anesthetic gases instead of releasing them unimpeded into the atmosphere.
-
Enhancing patient experience: Bridging digital care and energy consumption
Enhancing patient experience is one of Fresenius’ top priorities – and digitalization plays an important role in achieving this. In 2025, Quirónsalud launched a pilot project at a hospital in Southern Spain to connect our digital platform Casiopea with the hospital’s Building Management System.
Our pledge, Committed to Life, reflects our mission: To save lives and improve patients’ health and quality of life. Our employees bring this commitment to life every day – in direct patient care as well as in supporting functions across the Group.
Within our Sustainability Framework, people are at the center of our activities. We support patients at different stages of their lives and aim to expand access to high-quality and affordable healthcare and improve health outcomes. In doing so, we focus on patient-centered approaches that reflect individual needs and enable appropriate care.
We also recognize that our employees are key to delivering high-quality care. We aim to provide a working environment where they can contribute, develop, and make a meaningful impact.
Our Outreach
We treated
~ 27 m
patients in our hospitals in 2025.
We served
450 m
patients with our healthcare products in 2025.
The Human Dimension of our Sustainability Framework encompasses these focus topics:
Patient centricity at Fresenius means prioritizing multifaceted patient needs and experiences by providing holistic care through leading medical products and services – in inpatient and outpatient settings.
Every year, millions of people entrust us with their most precious asset: their health. With our expertise, we accompany our patients through health and illness: from human to human.
We set out to make our treatments more successful by providing high-quality care. This can help to shorten our patients’ hospital stays, enhance their quality of life – and improve patient satisfaction.
➔ Read more in our Sustainability Statement.
Digitalization plays a crucial role in shaping personalized and efficient processes in our hospitals as well as in the use of our products. We continuously digitize existing processes and introduce new digital workflows. Further, we leverage the capabilities of Artificial Intelligence to enhance the patient experience and expand treatment options, while ensuring its responsible use in accordance with ethical standards, data privacy regulations, and transparency principles.
➔ Read more in our Sustainability Statement.
We strive to provide affordable, high-quality products and services that are accessible and contribute to enhancing the efficiency of healthcare systems.
Our range of products and services includes the services of a broad network of clinics as well as high-quality pharmaceuticals and medical devices. We also use digitalization opportunities and develop new forms of therapy. In this way, we aim to reach as many people as possible with our healthcare services and products.
We are dedicated to advancing global health by prioritizing patient well-being and empowering employees. Our growing portfolio includes pharmaceuticals – generics and biosimilars – that offer cost-effective alternatives to originator drugs, and our MedTech and Nutrition products that establish a solid foundation for patient care and recovery.
Ensuring that our products are available is vital to patient care. We continuously invest in our global manufacturing network to maintain a reliable and resilient supply of life-saving therapies. By strengthening our supply infrastructure, we help to prevent disruptions and enhance healthcare delivery worldwide.
Strengthening our purpose-driven performance culture to attract, develop, and retain a motivated workforce is a key priority. They are the foundation to deliver medical care day-by-day.
Committed to Life – our nearly 180,000 employees put this promise into practice every day: whether in direct contact with patients, relatives, and business partners or behind the scenes in administration and production.
As an employer, it is our responsibility to provide good and safe working conditions for our employees. We seek direct interaction with our employees – because their wide variety of experiences and views help us to constantly improve. Providing our employees with the best possible support in the various phases of their careers while also promoting their commitment and development is very important to us.
Our Team
178583
people were employed by the Fresenius Group in 2025.
40.7
– was the average age of our employees in 2025.
Sustainability Insights
Explore our stories to learn what sustainability looks like in our daily operations:
-
How Fresenius Kabi supports access to essential therapies in everyday care
Healthcare progress is not only driven by major medical innovations. In everyday practice, reliable access to essential medicines, medical devices, and nutrition therapies is equally critical. Fresenius Kabi contributes to the stable availability of affordable, high quality therapies.
-
When every day counts: EASYGEN is set to make cell therapy more accessible
In severe cancer cases, time can become a critical factor. However, CAR-T cell therapy, a highly effective form of individually engineered immunotherapy, often takes a very long time to prepare and manage. This is where the EASYGEN project comes in.
-
Frembassadors: employees as ambassadors
What makes Fresenius so special as an employer? The people who work together here. We want their authentic everyday stories from the workplace to be seen by the outside world, which is why the Employer Branding team launched a special program: the Frembassadors.
-
Moments that create impact: How patient experience takes shape at Quirónsalud
A hospital stay is shaped not only by medical outcomes, but by everyday moments: a nurse who takes time to listen, a doctor who explains the next step clearly, or a team that works well together. At Quirónsalud, patient experience is understood as the sum of these moments.
-
What exactly is … a hospital cluster?
Fresenius Helios has grouped its roughly 80 hospitals in Germany into 21 clusters. The aim is to deliver patient care while further enhancing medical quality and efficiency.
Bonds 2023 – 2030
Issuer | Fresenius SE & Co. KGaA |
Currency | € |
Issue amount | 500,000,000 |
Value date | October 5, 2023 |
Maturity | October 5, 2030 |
Coupon | 5.125% |
Coupon payment | October 5 |
Rating | BBB / Baa3 / BBB- |
Stock exchange | Luxembourg / Regulated Market |
Denomination | 1,000 |
Clearing agency | Clearstream Luxembourg / Euroclear |
ISIN Code | XS2698713695 |
Financing Strategy & Targets
Ensure financial flexibility, maintain our investment grade rating, limit refinancing risks and optimize the cost of capital are the main objectives in Fresenius’s financing strategy.
To remain financially flexible, we maintain adequate liquidity headroom. We are committed to our investment grade rating, which provides us with advantages with respect to funding costs, facilitates markets access, and thus contributes to greater financial flexibility overall. Our financing strategy aims at ensuring a stable investment grade rating in the long term.
Refinancing risks are limited due to a balanced maturity profile which is characterized by a broad range of maturities with a high proportion of mid- and long-term debt. We use various financing instruments in a targeted manner to diversify our financing mix and our investor base.
Relevant financing instruments include bonds, Schuldschein Loans and bank loans. In addition, Fresenius maintains a commercial paper program.
Another key objective of Fresenius’ financing strategy is to optimize the cost of capital by employing an adequate mix of equity and debt.
In 2026, adherence to our self-imposed target corridor will continue to be of central importance to us. Our self-imposed target corridor of 2.5 x to 3.0 x allows us to stay financially flexible while solidifying our investment grade rating.
Fresenius Group
1 Prior-year figures have been adjusted due to the deconsolidation of Fresenius Medical Care
2 Before special items
3 At LTM average exchange rates for both net debt and EBITDA; pro forma acquisitions/divestitures; including lease liabilities; including Fresenius Medical Care and Vitrea dividends; net debt adjusted for the valuation effect of the exchangeable bond
Financing Instruments
Bonds
| Issuer | Volume in million | Coupon | Maturity |
|---|---|---|---|
| €500 | 0.375% | 2026 | |
| €750 | 1.625% | 2027 | |
| €750 | 0.75% | 2028 | |
| CHF275 | 2.96% | 2028 | |
| €500 | 2.875% | 2029 | |
| CHF225 | 1.5975% | 2029 | |
| €500 | 5.00% | 2029 | |
| €500 | 2.75% | 2029 | |
| €550 | 2.875% | 2030 | |
| €500 | 5.125% | 2030 | |
| €500 | 1.125% | 2033 | |
| €500 | 3.50% | 2034 | |
| €700 | 2.125% | 2027 | |
| €500 | 0.50% | 2028 | |
| €500 | 0.875% | 2031 | |
| €500 | 3.00% | 2032 |
Schuldschein loans
| Issuer | Volume in million | Interest rate fixed/variable | Maturity |
|---|---|---|---|
Fresenius SE & Co. KGaA | €117 | 0.85% | 2026 |
Fresenius SE & Co. KGaA | €207 | 1.96%/variable | 2027 |
Fresenius SE & Co. KGaA | €101 | 4.62% | 2028 |
Fresenius SE & Co. KGaA | €84 | 1.10% | 2029 |
Fresenius SE & Co. KGaA | €66 | 4.77% | 2030 |
EIB loan
| Issuer | Volume in million | Coupon | Maturity |
|---|---|---|---|
Fresenius SE & Co. KGaA | €400 | variable | 2030 |
The European Investment Bank (EIB) is the biggest multilateral financial institution in the world and one of the largest providers of finance for climate action, providing economic support to sectors that contribute significantly to technological innovation, growth, employment, regional cohesion and environmental sustainability in Europe and beyond.
Fresenius received a €400 million loan in December 2025 to strengthen its European research and development (R&D) activities. The financing is used to support expansion of Fresenius Kabi's manufacturing of medical products and biosimilars in European countries.
The Fresenius SE & Co. KGaA Commercial Paper Program enables Fresenius to issue short-term notes of up to €1.5 bn on the money market. The issuances are made through the European Commercial Paper Program (ECP).
| Issuer: |
Fresenius SE & Co. KGaA, Fresenius Finance Ireland plc. |
| Program amount | € 1,500,000,000 |
| Arranger |
Commerzbank |
| Dealer |
Barclays, Commerzbank, Crédit Agricole, DZ BANK AG, Landesbank Baden-Württemberg, Landesbank Hessen-Thüringen, ING Bank N.V. |
| Issuing and paying agent | Commerzbank |
| Term | up to 1 year less 1 day |
Rating
Fresenius is covered by the leading rating agencies Standard & Poor's, Moody's and Fitch. The following table shows Fresenius SE & Co. KGaA's current ratings.
Rating
| Standard & Poor's | Moody's | Fitch | |
|---|---|---|---|
Corporate Credit Rating | BBB | Baa3 | BBB- |
Outlook | positive | stable | stable |
Contact
Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com
New information
Related Links
Interactive Tool
Fresenius today officially opened its new Innovation Center in Bad Homburg, Germany, marking a major milestone in strengthening research, development, and innovation in medical nutrition. The state-of-the-art laboratory, modern IT infrastructure and office facility accelerates new product development and drives innovation-led growth. In addition, it underscores Fresenius’ commitment to advancing patient care through science-based solutions and reinforces Europe as a key hub for healthcare.
“With the new Innovation Center, we are further embedding science in our Fresenius campus in Bad Homburg, strengthening collaboration and enabling fast, integrated decision-making. This is a clear commitment to our mission of improving patients’ lives through high-quality, accessible medical nutrition.” emphasized Sara Hennicken, CFO of Fresenius, who is also responsible for real estate within the group, and host of the opening ceremony.
Under the guiding theme A New Chapter for Medical Nutrition, the new center will bring approximately 100 experts from multiple disciplines under one roof, fostering collaboration, execution excellence, and innovation. By consolidating previously decentralized teams, Fresenius is creating a highly integrated environment to accelerate the development of next-generation nutritional therapies.
Nutrition as a cornerstone of patient health
Medical nutrition plays a critical and often underrecognized role in patient outcomes. Particularly for individuals suffering from malnutrition, a condition that can significantly affect recovery, hospital stays, and overall quality of life. The Innovation Center will focus on advancing enteral nutrition solutions, including the development of products within the company’s portfolio designed to meet the needs of vulnerable patient populations. In parallel, it drives the development of automated pumping systems for patient-specific compounding of sterile ingredients into bags for parenteral nutrition (PN) solutions. This enables the preparation of tailored micro- and macronutrient PN admixtures while reducing the need for manual additions.
“Innovation is at the heart of everything we do,” said Dr. Marc-Alexander Mahl, President Pharma, Nutrition and Sustainability. “By combining scientific excellence with a deep understanding of patients’ needs, we are developing nutritional solutions that make a tangible difference in clinical practice and everyday life.”
At the center of the current strategic phase Rejuvenate is growth through innovation. The new facility embodies Fresenius’ broader ambition to translate scientific insights into practical healthcare solutions. As part of its long-term strategy, the company is investing in innovative platforms that bridge science and patient needs in line with #FutureFresenius.
With more than €50 million invested in the overall Bad Homburg campus in recent years, the Innovation Center adds to Fresenius’ ability to develop future-oriented therapies and contribute to resilient healthcare systems. It also demonstrates the continued commitment of Fresenius to its local-for-local approach not only when it comes to production but also in research and development.
Opening ceremony with distinguished participants
The opening ceremony brought together representatives from different functions, highlighting Fresenius leadership, research, and local government, including Sara Hennicken, CFO Fresenius, Alexander Hetjes, Mayor of Bad Homburg, Pierluigi Antonelli, CEO Fresenius Kabi, Dr. Marc-Alexander Mahl, President Pharma, Nutrition and Sustainability, and José Mainou, SVP R&D Enteral Nutrition Fresenius Kabi. Their presence highlighted the significance of the new center for both the company and the regional innovation ecosystem.
“Bad Homburg and Fresenius have been closely connected for decades,” said Mayor Alexander Hetjes. “The company plays a particularly significant role in shaping our city economically and as an employer. At the same time, Bad Homburg offers an environment in which innovation, growth, and international talent find ideal conditions. It is a strong signal that Fresenius is investing here at the Bad Homburg site in research, development, and future viability.”
A strong signal for the future
The new Innovation Center reflects Fresenius’ commitment to patient-centricity, operational excellence, and technological leadership. By investing in cutting-edge infrastructure and interdisciplinary collaboration, the company is strengthening its ability to shape the future of medical nutrition, directly benefiting patients, healthcare systems, and society as a whole.
Fresenius (XFRA: FRE, OTCQX: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, clinical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually. With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.
For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch
New ready-to-use three-chamber bag parenteral nutrition solution strengthens Fresenius’ global clinical nutrition portfolio and reflect its commitment to patient centric innovation
Fresenius, a global healthcare company, today announced the European launch of the Pedismof® range, a new ready to use three chamber bag for pediatric parenteral nutrition. Developed by Fresenius Kabi, the introduction marks an important milestone within the clinical nutrition portfolio and aligns with the Company’s #FutureFresenius strategy to foster patient centric innovation, simplify care, and support patient access to essential therapies.
The range offers age-specific formulations for preterm and term neonates, infants, children, and adolescents, supporting standardized pediatric parenteral nutrition. It is the third product launch this year in the company’s clinical nutrition branch.
The three chamber bag combines glucose, amino acids with a balanced profile, and the lipid emulsion SMOFlipid®, which contains fish oil and omega 3 fatty acids. The formulation has been developed in line with established European pediatric nutrition guidelines1 and is available in multiple volumes to meet the nutritional requirements of most patients.
“The Pedismof® range is an example of how our clinical nutrition portfolio continues to evolve to address specific clinical and patient needs,” said Dr. Marc Alexander Mahl, President Pharma, Nutrition and Sustainability at Fresenius Kabi. “With age appropriate formulations and a ready to use design, we aim to support healthcare professionals in the delivery of neonatal and pediatric parenteral nutrition within established clinical frameworks.”
Just a few days ago – on June 2nd, Fresenius opened an Innovation Center in Germany focused specifically on clinical nutrition. The new center will bring approximately 100 experts from multiple disciplines under one roof, fostering collaboration and speed to continuously develop new products.
This launch is a further proof point of the company’s current strategy phase Rejuvenate by strengthening Fresenius’ clinical nutrition portfolio and underscores the Company’s focus on scalable, system relevant therapies that contribute to long term patient access and differentiated health outcomes.
Availability of Pedismof® range may vary by country and are subject to local regulatory approvals.
1Van Goudoever JB et al. Clin Nutr. 2018;37(6 Pt B):2315-2323. Lapillonne A et al. Clin Nutr. 2018;37(6 Pt B):2324-2336. Joosten K et al. Clin Nutr. 2018;37(6 Pt B):2309-2314. Mesotten D et al. Clin Nutr. 2018;37(6 Pt B):2337-2343. Mihatsch W et al. Clin Nutr. 2018;37(6 Pt B):2360-2365. Jochum F et al. Clin Nutr. 2018;37(6 Pt B):2344-2353.
Fresenius (XFRA: FRE, OTCQX: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, clinical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually. With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.
For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch
Our Sustainability Framework
Our mission is to save and improve human lives. Sustainability helps us deliver on this mission by focusing on opportunities that arise from sustainable business practices and turning them into measurable progress.
Our approach built on a unique corporate legacy spanning more than a century and is guided by strong principles and a clear direction for the future.
Our Sustainability Framework translates this approach into action. It structures our activities across three dimensions and nine focus topics, providing clear orientation and a consistent direction across the Group.
We focus on three core dimensions:
“For us, sustainability is not just a buzzword. It's our responsibility and our strength. It makes us competitive and resilient, ensuring our success. Both today and tomorrow.”
Dr. Michael Moser, Member of the Fresenius Management Board, responsible for Legal, Compliance, Risk Management, Sustainability, Human Resources, Corporate Audit and Vamed
Our Goals and Progress
Since we can only improve what we understand and control, we have set ourselves goals along our business activities – for the Group as a whole and for the individual operating companies.
At Fresenius, sustainability is an important responsibility of the Management Board: As a key component of our business strategy, sustainability targets are also included in the variable compensation of the Management Board.
Our Sustainability Governance
Effective governance is essential for us to understand and actively manage our activities. It provides the structure and accountability needed to ensure that our sustainability ambitions are not just aspirations, but actions. Through an integrated approach, we turn isolated initiatives into meaningful progress.
Clear ownership and strong collaboration
At Fresenius, overall responsibility for sustainability lies with the Fresenius Management Board member responsible for Legal, Compliance, Risk Management, Sustainability, Human Resources, Corporate Audit and Fresenius Vamed.
The Group Sustainability function serves as the central competence center for sustainability across the Group. It monitors regulatory developments, identifies material topics, defines strategic priorities and opportunities to drive implementation of our Sustainability Framework. It supports the Group-wide rollout of sustainability initiatives. It is also responsible for sustainability-related internal and external stakeholder communication and, together with Global Accounting, for non-financial reporting.
The Group Sustainability Committee defines the company-wide approach, monitors progress, and oversees its implementation – both overall and across the individual focus topics. Dedicated working groups throughout the organization drive these topics forward and ensure their operational execution.
The Management Board and the Supervisory Board review the progress and the results of the sustainability management across the Group.
"We focus our sustainability efforts where they create the greatest impact for people, the planet, and our business. With clear goals and close monitoring, we systematically embed sustainability across every part of our operations."
Sarah Tix, Head of Group Sustainability, Fresenius Group
Our Sustainability Advisory Board
Fresenius has appointed an independent Sustainability Advisory Board. Four leading international experts from science, business, and consulting are supporting us in further developing our related activities.
Image from left to right: Fabian Kienbaum, Dr. Fiona Adshead, Dr. Michael Moser (Member of the Management Board), Anahita Thoms (Chair) and Prof. Dr. Judith Walls.
-
Sustainability Perspectives
Gain insights into our recent activities and meet the colleagues driving our efforts.
Meeting of the Sustainability Advisory Board at Quirónsalud: Human-Centered Care in Focus
How digital innovation and value-based healthcare are transforming the provision of healthcare services and enabling patient-centered, sustainable solutions was the focus of Fresenius’ Sustainability Advisory Board meeting held in Madrid in June 2025.
-
Sustainability Perspectives
Gain insights into our recent activities and meet the colleagues driving our efforts.
Sustainability at Fresenius: Five Questions for Sarah Tix, Head of Group Sustainability
"In our view, sustainability management represents a real opportunity and is essential for securing the resilience, competitiveness, and long-term success of companies."
-
Sustainability Perspectives
Gain insights into our recent activities and meet the colleagues driving our efforts.
Meeting of the Sustainability Advisory Board at Fresenius Kabi: Driving Sustainability in Manufacturing
At the first SAB meeting of 2025, held at the Fresenius Kabi production site in Friedberg, Germany, a range of topics related to advancing our sustainability efforts, especially in manufacturing, were discussed – from water management to human rights due diligence.
-
Sustainability Perspectives
Gain insights into our recent activities and meet the colleagues driving our efforts.
Climate Protection: Three questions for Mapi Henríquez de Armas, Director Sustainability at Quirónsalud
"While adapting to climate change is managed at a local level, we have set global emission reduction targets that help us to meet related expectations and to coordinate our efforts."
You would like to learn more about the specific sustainability activities of our operating companies? Have a look at their dedicated websites: